Cart
sales@molnova.com
Naroparcil
CAS No. 120819-70-7
Naroparcil( —— )
Catalog No. M36130 CAS No. 120819-70-7
Naroparcil, an orally available thioglycoside analog of 4-methylumbelliferyl β-D-xyloside, showed antithrombotic effects in the Wessler sludge model of venous thrombosis (jugular vein).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 471 | Get Quote |
|
| 5MG | 719 | Get Quote |
|
| 10MG | 1007 | Get Quote |
|
| 25MG | 1454 | Get Quote |
|
| 50MG | 1960 | Get Quote |
|
| 100MG | 2583 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameNaroparcil
-
NoteResearch use only, not for human use.
-
Brief DescriptionNaroparcil, an orally available thioglycoside analog of 4-methylumbelliferyl β-D-xyloside, showed antithrombotic effects in the Wessler sludge model of venous thrombosis (jugular vein).
-
DescriptionNaroparcil, an orally available thioglycoside analog of 4-methylumbelliferyl β-D-xyloside, showed antithrombotic effects in the Wessler sludge model of venous thrombosis (jugular vein).Naroparcil enhanced the formation of the thrombin/heparin cofactor II complex, induced dermatophyte sulfate-like substances in plasma from treated rabbits appearance, but reduced the formation of thrombin/antithrombin III complexes in plasma incubated with (125I)-human alpha-thrombin.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAutophagy
-
TargetThrombin
-
RecptorThrombin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number120819-70-7
-
Formula Weight387.47
-
Molecular FormulaC19H17NO4S2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESS(C1=CC=C(C(=O)C2=CC=C(C#N)C=C2)C=C1)[C@H]3[C@H](O)[C@@H](O)[C@H](O)CS3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Etamsylate
Ethamsylate is a haemostatic drug, which inhibits biosynthesis and action of prostaglandins, and increases capillary endothelial resistance as and platelet adhesion.
-
Enoxaparin sodium
Enoxaparin sodium is a low-molecular-weight heparin (LMWH) that has recently been approved by the US FDA for use in patients with medically managed ST-segment myocardial infarction (STEMI), or STEMI with subsequent percutaneous coronary intervention (PCI).
-
Dabigatran etexilate...
A prodrug of BIBR-953, which is a potent nonpeptide thrombin inhibitor with Ki of 4.5 nM.
